School of Medicine
Showing 341-350 of 481 Results
-
Darren Salmi
Clinical Assistant Professor, Pathology
Current Research and Scholarly InterestsCardiovascular pathology, congenital heart disease, autopsy, medical education
-
Matteo Santoro Pharm.D., Ph.D.
Postdoctoral Scholar, Pathology
BioDr. Santoro joined Shamloo’s lab in March 2021 focusing his research on Parkinson’s disease, neuronal vulnerability, and identification of therapeutic markers in relation to α-synucleinopathies. Prior to his arrival at Stanford, he held a position as a clinical monitor at Syneos Health where he gained key knowledge needed to translate lab-based findings into clinical and commercial applications. Previously, Dr. Santoro held a postdoctoral position at the University of Aberdeen (Scotland, UK) working on amyloid-beta extracts from Alzheimer’s disease patients. During his postdoctoral research, Dr. Santoro designed and optimized a cost-effective and rapid assay for the measurement of toxic amyloid-beta species in human biofluids. In 2017, he obtained his Ph.D. (4-year program) at the University of Aberdeen on Parkinson’s disease (PD), immunology, and behavior. The major findings Ph.D. findings were the following: 1) the characterization of a small protein called HMGB1 as an inflammatory mediator in PD; 2) the motor and non-motor behavioral characterization of three neurotoxin based mouse models of PD, 3) the characterization of the innate immune response in PD through the toll-like receptor signaling pathways 4) evaluation of the effects of chronic systemic inflammation on both resident and infiltrating immune cells in the CNS. In 2012 Dr. Santoro attained his Pharm.D. in chemistry and pharmaceutical technology (5-year program) at the University of Calabria (Italy) during which he undertook an internship at the King’s College London (SGDP Centre) and worked for over a year on a rat model of stroke.
-
Ansuman Satpathy
Assistant Professor of Pathology
Current Research and Scholarly InterestsOur lab works at the interface of immunology, cancer biology, and genomics to study cellular and molecular mechanisms of the immune response to cancer. In particular, we are leveraging high-throughput genomic technologies to understand the dynamics of the tumor-specific T cell response to cancer antigens and immunotherapies (checkpoint blockade, CAR-T cells, and others). We are also interested in understanding the impact of immuno-editing on the heterogeneity and clonal evolution of cancer.
We previously developed genome sequencing technologies that enable epigenetic studies in primary human immune cells from patients: 1) 3D enhancer-promoter interaction profiling (Nat Genet, 2017), 2) paired epigenome and T cell receptor (TCR) profiling in single cells (Nat Med, 2018), 3) paired epigenome and CRISPR profiling in single cells (Cell, 2019), and high-throughput single-cell ATAC-seq in droplets (Nature Biotech, 2019). We used these tools to study fundamental principles of the T cell response to cancer immunotherapy (PD-1 blockade) directly in cancer patient samples (Nature Biotech, 2019; Nat Med, 2019).
